MCID: DMY001
MIFTS: 41

Demyelinating Polyneuropathy

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 15
Peripheral Demyelinating Neuropathy 12 71
Demyelinating Peripheral Neuropathy 6

Classifications:



External Ids:

Disease Ontology 12 DOID:5214
NCIt 50 C27062
SNOMED-CT 67 23414001
UMLS 71 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to guillain-barre syndrome and polyneuropathy. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Spinal Cord Injury and Cell adhesion molecules. The drugs gamma-Globulins and Rho(D) Immune Globulin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and spinal cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Subacute Inflammatory Demyelinating Polyneuropathy Acute and Subacute Inflammatory Demyelinating Polyneuropathy
Chronic Acquired Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 guillain-barre syndrome 32.6 PMP22 HP ALB
2 polyneuropathy 31.3 TTR PMP22 NGF NFASC MAG IFNA2
3 multifocal motor neuropathy 31.2 FCGR2B CNTN2
4 neuropathy 31.2 TTR PMP22 NGF NFASC MAG ALB
5 sensory peripheral neuropathy 31.2 PMP22 NGF MAG
6 chronic polyneuropathy 30.9 MAG FCGR2B
7 polyradiculopathy 30.7 NFASC CNTN1
8 demyelinating disease 30.7 PMP22 NGF MMP9 MAG
9 autoimmune neuropathy 30.6 NFASC MAG FCGR2B CNTN1
10 miller fisher syndrome 30.6 NFASC MAG CNTN1 ALB
11 mononeuropathy 30.6 TTR PMP22 NGF MAG ALB
12 peripheral nervous system disease 30.5 TTR PMP22 NGF NFASC MMP9 MAG
13 nerve compression syndrome 30.4 TTR PMP22 NGF ALB
14 median neuropathy 30.4 TTR PMP22
15 autoimmune disease 30.2 TNFSF13B MMP9 FCGR2B CD1D AIRE
16 autonomic neuropathy 30.1 TTR NGF ALB
17 meningoencephalitis 30.1 NGF CLDN5 ALB
18 autoimmune peripheral neuropathy 30.1 MAG AIRE
19 corneal disease 30.0 NGF MMP9 ALB
20 central nervous system disease 29.9 TTR NGF MMP9 ALB
21 thrombocytopenia 29.7 TNFSF13B MMP9 IFNA2 HP FCGR2B ALB
22 chronic kidney disease 29.6 TTR PTGDS MMP9 HP ALB
23 malaria 29.4 TNFSF13B MMP9 HP FCGR2B ALB AIF1
24 multiple sclerosis 28.8 TNFSF13B PTGDS NGF MMP9 MAG CD52
25 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 11.9
26 chronic inflammatory demyelinating polyradiculoneuropathy 11.9
27 guillain-barre syndrome, familial 11.6
28 neurodevelopmental disorder with central and peripheral motor dysfunction 11.3
29 chronic acquired demyelinating polyneuropathy 11.2
30 subacute inflammatory demyelinating polyneuropathy 11.2
31 lewis-sumner syndrome 11.1
32 acute and subacute inflammatory demyelinating polyneuropathy 11.1
33 charcot-marie-tooth disease and deafness 11.1
34 marinesco-sjogren syndrome 11.1
35 charcot-marie-tooth disease, type 4k 11.1
36 neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities 11.1
37 mannosidosis, beta a, lysosomal 11.1
38 canomad syndrome 11.1
39 polyradiculoneuropathy 10.7
40 ataxia and polyneuropathy, adult-onset 10.5
41 respiratory failure 10.5
42 charcot-marie-tooth disease 10.5
43 axonal neuropathy 10.5
44 tooth disease 10.4
45 hereditary neuropathies 10.4
46 myasthenia gravis 10.4
47 quadriplegia 10.4
48 poems syndrome 10.4
49 tremor 10.4
50 lesion of sciatic nerve 10.4 PMP22 NGF

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 AIRE CD1D CNTN1 CNTN2 FCGR2B GAS6
2 homeostasis/metabolism MP:0005376 10.1 AIF1 AIRE ALB CD1D FCGR2B GAS6
3 cardiovascular system MP:0005385 10.02 AIF1 ALB CD1D CLDN5 FCGR2B GAS6
4 immune system MP:0005387 9.9 AIF1 AIRE ALB CD1D FCGR2B GAS6
5 mortality/aging MP:0010768 9.77 AIRE ALB CD1D CLDN5 CNTN1 FCGR2B
6 nervous system MP:0003631 9.44 AIF1 AIRE CD1D CLDN5 CNTN1 CNTN2

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 gamma-Globulins Phase 4
2 Rho(D) Immune Globulin Phase 4
3
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
4
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
5 Anti-Inflammatory Agents Phase 3
6 glucocorticoids Phase 3
7 Antineoplastic Agents, Hormonal Phase 3
8
rituximab Approved Phase 2 174722-31-7 10201696
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
10
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 171548
11 Thymoglobulin Phase 2
12 Trace Elements Phase 2
13 Micronutrients Phase 2
14 Vitamin B Complex Phase 2
15 Vitamin B7 Phase 2
16 Vitamins Phase 2
17 Folate Phase 2
18 Vitamin B9 Phase 2
19 Nutrients Phase 2
20 Protective Agents Phase 2
21 Antioxidants Phase 2
22 Alpha-lipoic Acid Phase 2
23 Thioctic Acid Phase 2
24 Immunoglobulins Phase 2
25 Immunologic Factors Phase 2
26 Immunoglobulins, Intravenous Phase 2
27 Antibodies Phase 2
28 Immunoglobulin G Phase 2
29 Autoantibodies Phase 2
30 Pharmaceutical Solutions Phase 2
31 Antineoplastic Agents, Immunological Phase 2
32 Complement System Proteins Phase 2
33 Antibodies, Monoclonal Phase 2
34 Antibodies, Anti-Idiotypic

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy Recruiting NCT04589299 Phase 4
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
4 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
5 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
6 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
7 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
8 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
9 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
10 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
12 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Completed NCT00278629 Phase 2
13 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
14 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
15 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
16 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
17 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04280718 Phase 2
18 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Active, not recruiting NCT03864185 Phase 2
19 Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Not yet recruiting NCT04480450 Phase 2 Rituximab
20 A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT04658472 Phase 2 BIVV020
21 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
22 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
23 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT02465359 Immune Globulin Subcutaneous (Human)
24 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
25 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
26 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
27 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
28 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
29 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) Completed NCT02414490 Intravenous Immunoglobulin
30 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733
31 A Registered Cohort Study of Immune-Mediated Neuropathies Active, not recruiting NCT04292834
32 Hizentra® in Inflammatory Neuropathies - pHeNIx Study Not yet recruiting NCT04672733
33 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Standard of Care
34 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Terminated NCT03779828

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

40
T Cells, Bone Marrow, Spinal Cord, Endothelial, Skin, B Cells, Lymph Node

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 2472)
# Title Authors PMID Year
1
Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. 61
33376111 2021
2
CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups: An Autoantigenomic Approach. 61
33408168 2021
3
Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. 61
33340200 2021
4
X-linked adrenoleukodystrophy caused by a novel mutation presenting with various phenotypes in a Taiwanese family. 61
33359056 2021
5
Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. 61
33078247 2021
6
Focal Sensory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). 61
33594681 2021
7
Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies. 61
33146871 2021
8
Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review. 61
33563801 2021
9
Correction to: A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. 61
33439475 2021
10
Genetic neuropathies presenting with CIDP-like features in childhood. 61
33386210 2021
11
Impact of psychiatric distress and physical disability on quality of life in neuromyelitis optica spectrum disorder and chronic autoimmune demyelinating polyneuropathies. 61
33383364 2021
12
[Pronounced proximally accentuated changes in high-voltage stimulation and nerve ultrasound in long-standing therapy-naive CIDP variants]. 61
33112965 2021
13
Complication of Hepatitis A Infection: Case Report of Acute Inflammatory Demyelinating Polyneuropathy. 61
33560967 2021
14
Acute Demyelinating Polyneuropathy in a Child with Dengue Shock Syndrome. 61
32542487 2021
15
COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy. 61
33606069 2021
16
Semi-Automatic MRI Muscle Volumetry to Diagnose and Monitor Hereditary and Acquired Polyneuropathies. 61
33562055 2021
17
Magnetic resonance neurography in diagnosing childhood chronic inflammatory demyelinating polyradiculoneuropathy. 61
33433331 2021
18
Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features. 61
33598798 2021
19
Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy. 61
33111308 2021
20
Four mutations in MITF, SOX10 and PAX3 genes were identified as genetic causes of waardenburg syndrome in four unrelated Iranian patients: case report. 61
33557787 2021
21
Successful Nucleoside Analog and Corticosteroid Therapy for Chronic Inflammatory Demyelinating Polyneuropathy in a Patient With Hepatitis B Virus Liver Cirrhosis. 61
33457438 2021
22
Increased muscle echointensity correlates with clinical disability and muscle strength in chronic inflammatory demyelinating polyneuropathy. 61
33404183 2021
23
Application of CMAP scan for the evaluation of patients with chronic inflammatory demyelinating polyneuropathy: a prospective study. 61
33423829 2021
24
Early axonal loss predicts long-term disability in chronic inflammatory demyelinating polyneuropathy. 61
33581994 2021
25
Psychometric longitudinal evaluation of the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) in patients with chronic inflammatory demyelinating polyneuropathy. 61
33043466 2021
26
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. 61
33039291 2021
27
A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. 61
33113101 2021
28
Changes in motor nerve excitability in acute phase Guillain-Barré syndrome. 61
33452679 2021
29
Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. 61
33540321 2021
30
Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection. 61
33045420 2021
31
Guillain-Barre Syndrome Amid Osteosarcoma Treatment: A Therapeutic Dilemma and Literature Review. 61
33542879 2021
32
[Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors]. 61
33361512 2021
33
New evidence for secondary axonal degeneration in demyelinating neuropathies. 61
33359733 2021
34
Acute Brucellosis with a Guillain-Barre Syndrome-Like Presentation: A Case Report and Literature Review. 61
33401372 2021
35
Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. 61
33272955 2021
36
Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. 61
33404110 2020
37
Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. 61
32410146 2020
38
Dissociation of axo-glial junction in anti-neurofascin 155 chronic inflammatory demyelinating polyneuropathy. 61
33261722 2020
39
Peripheral Nerve Enlargement in Chronic Inflammatory Demyelinating Polyneuropathy. 61
33390487 2020
40
Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies. 61
32875645 2020
41
Fatigue in chronic inflammatory demyelinating polyneuropathy. 61
32710648 2020
42
Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy. 61
32893348 2020
43
Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy. 61
32794258 2020
44
Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits? 61
33035867 2020
45
Electrophysiology of fatigue in chronic inflammatory demyelinating polyneuropathy: Can it be useful? 61
33250076 2020
46
High Levels of Il-19 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. 61
32472395 2020
47
Peripheral nerve electrophysiology studies in relation to fatigue in patients with chronic inflammatory demyelinating polyneuropathy. 61
32928696 2020
48
Clinical, electrophysiological and genetic characteristics of childhood hereditary polyneuropathies. 61
32709422 2020
49
Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies. 61
32876980 2020
50
Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy. 61
33376152 2020

Variations for Demyelinating Polyneuropathy

ClinVar genetic disease variations for Demyelinating Polyneuropathy:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIF5A NM_004984.4(KIF5A):c.2005G>A (p.Ala669Thr) SNV Uncertain significance 816537 rs142495781 12:57969522-57969522 12:57575739-57575739

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.34 TNFSF13B MMP9 MAG AIF1
2 11.19 NFASC MAG CNTN2 CNTN1 CLDN5

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TTR TNFSF13B PTGDS NGF MMP9 IFNA2
2 node of Ranvier GO:0033268 9.37 NFASC CNTN2
3 paranode region of axon GO:0033270 9.32 MAG CLDN5
4 extracellular space GO:0005615 9.32 TTR TNFSF13B PTGDS NGF MMP9 IFNA2
5 Schmidt-Lanterman incisure GO:0043220 9.26 MAG CLDN5
6 anchored component of postsynaptic membrane GO:0099025 8.96 CNTN2 CNTN1

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.72 NGF MMP9 GAS6 ALB AIF1
2 transmission of nerve impulse GO:0019226 9.37 NFASC MAG
3 positive regulation of T cell proliferation GO:0042102 9.33 TNFSF13B CD1D AIF1
4 central nervous system myelination GO:0022010 9.26 MAG CNTN2
5 cerebellum development GO:0021549 9.13 FCGR2B CNTN1 AIF1
6 peripheral nervous system development GO:0007422 8.8 PMP22 NGF NFASC

Sources for Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....